Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New Developments Oct 28, 2022 02:00AM
Bryan Garnier & Co Initiates the Coverage of Quantum Genomics with a Target Price at 13€ per Share Oct 6, 2022 12:00PM
Quantum Genomics Publishes its 2022 First Half Results and Reviews its Activity Oct 5, 2022 12:00PM
Quantum Genomics Announces That the Results Obtained with Firibastat in its Phase III Study, FRESH Will Now be Presented on November 7, 2022, During the AHA Conference in a Session Dedicated to Resist Sep 26, 2022 10:06AM
Quantum Genomics announces the appointment of its new Scientific Advisory Board Jun 27, 2022 12:47PM


May 9, 2022 12:00PM Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH
May 4, 2022 12:00PM Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs
Apr 28, 2022 12:00PM Quantum Genomics Publishes its Results for Fiscal Year 2021 and Provides a Corporate Update
Apr 27, 2022 08:20AM Quantum Genomics Announces Successful Capital Raise with a Gross Sum of Approximately 15.6M€
Apr 26, 2022 11:35AM Quantum Genomics Raises a Gross Amount of Approximately € 15 M
Mar 31, 2022 12:00PM Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606
Mar 28, 2022 01:35PM Quantum Genomics Announces Granting of New Patents Protecting QGC606
Mar 14, 2022 01:00PM Stéphane Cohen Joins Quantum Genomics as Director of Global Operations
Dec 6, 2021 02:00AM Quantum Genomics Signs an Exclusive License and Production Agreement with Gulf Pharmaceuticals Industries Julphar
Nov 25, 2021 12:00PM Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.
Oct 7, 2021 12:00PM Quantum Genomics and its Partners Reach a New Stage of Development in Asia
Aug 27, 2021 04:45AM Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting
Jul 8, 2021 02:00AM Quantum Genomics Enrolls First Patient in Its Pivotal Phase III REFRESH Trial of Firibastat in Difficult-to-Treat and Resistant Hypertension with Once-a-Day Formulation of Firibastat
Jul 5, 2021 02:00AM Presentation of the Effects of QGC606 in an Experimental Model of Heart Failure at the Annual Congress of the European Society of Cardiology
May 19, 2021 12:40PM Quantum Genomics Announces the Publication of New Scientific Article in Biomedicine & Pharmacotherapy Which Further Strengthens its Phase III Development Plan in Difficult to Treat and Resistant H
Apr 28, 2021 12:03PM Quantum Genomics Secures €3 Million Non-dilutive Financing
Apr 21, 2021 02:00AM Quantum Genomics Will Present Top-line Results From its QUORUM Study of Firibastat in Heart Failure Post Myocardial Infarction at the European Society of Cardiology (ESC) Meeting
Apr 20, 2021 02:00AM Quantum Genomics Announces the End of its Collaboration with Qilu for the Development and Commercialization of Firibastat in China
Mar 25, 2021 01:00PM Quantum Genomics Reports Full Year 2020 Operating and Financial Results
Feb 9, 2021 12:00PM Orient EuroPharma Acquires Equity Stake in Quantum Genomics
Jan 18, 2021 03:30PM Quantum Genomics Launches Phase III Pivotal REFRESH Study in Difficult-to-treat/Resistant Hypertension with Once-a-day Formulation of Firibastat
Dec 16, 2020 02:00AM Quantum Genomics Signs a Strategic Contract with Delpharm
Dec 15, 2020 02:00AM Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran
Dec 2, 2020 11:50AM Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm
Nov 2, 2020 12:00PM Quantum Genomics Announces End of Financing Agreement with Negma Group Ltd/Park Partners
Oct 28, 2020 02:00AM Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals
Oct 19, 2020 02:00AM Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical
Sep 22, 2020 12:00PM Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Orient EuroPharma (OEP)
Jul 13, 2020 02:00AM Quantum Genomics Enrolls First Patient in Its Pivotal Phase III FRESH Trial of Firibastat in Difficult-to-treat and Resistant Hypertension
May 6, 2020 12:00PM Quantum Genomics Announces Interim Analysis from Study of Firibastat in Renal Failure Patients
Apr 7, 2020 12:00PM Quantum Genomics Provides Update on the Impact of the COVID-19 Health Crisis on Clinical Research Activities
Mar 31, 2020 09:52AM Quantum Genomics Secured New Financing, Published its Financial Statements for Fiscal Year 2019 and Provides 2019 Highlights
Jan 28, 2020 01:30AM Quantum Genomics Appoints Benoît Gueugnon as Vice President of Finance
Jan 15, 2020 12:00PM Quantum Genomics to Present at the Gordon Research Conference 2020 Dedicated to the Renin Angiotensin Aldosterone System
Dec 19, 2019 12:00PM Quantum Genomics Initiates its Pivotal Phase III FRESH Trial in Difficult-to-Treat and Resistant Hypertension
Dec 16, 2019 12:00PM Quantum Genomics to Participate in Biotech Showcase 2020
Dec 9, 2019 12:00PM Quantum Genomics and Biolab Sanus Pharmaceutical Enter into Exclusive Licensing and Collaboration Agreement for Firibastat in Latin America
Oct 7, 2019 01:30AM Quantum Genomics Enters Into Exclusive Negotiations for its First Partnership